ALPS Medical Breakthroughs ETFSBIO
Type
ETF
Peer group
US equity: Healthcare
Net assets
$138.0M
Expense ratio
0.50%
1-year return
+92.0%
3 years, a year
+32.6%
5 years, a year
+8.1%
12-month yield
0.00%
Holdings
92
What it aims to do.
The Fund seeks investment results that correspond (before fees and expenses) generally to the performance of its underlying index, the S-Network Medical Breakthroughs Index (ticker symbol PMBI) (the Underlying Index).
Top 10 holdings.
| Holding | % of fund |
|---|---|
| KYMR Kymera Therapeutics Inc | 4.66% |
| CELC Celcuity Inc | 3.34% |
| ALKS Alkermes Plc | 3.21% |
| CGON Cg Oncology Inc | 3.06% |
| MIRM Mirum Pharmaceuticals Inc | 3.06% |
| Amicus Therapeutics Inc | 2.86% |
| ACAD Acadia Pharmaceuticals Inc | 2.68% |
| NAMS Newamsterdam Pharma Co Nv | 2.60% |
| Crinetics Pharmaceuticals Inc | 2.52% |
| Apogee Therapeutics Inc | 2.48% |
More on SBIO.
- SBIO overview
- SBIO holdings
- SBIO risk
- SBIO costs
- SBIO money in and out
- SBIO share classes
- Compare SBIO with other funds
Returns after fees, from the fund's SEC filings up to Aug 2026. Past returns are not a promise. Not financial advice.